IND PROCEDURES – Regulatory Assistance

September 1, 2021

Infographic: US FDA IND Procedures – Regulatory Assistance

Current US law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. The IND is the means through which the sponsor technically obtains this exemption from the FDA.

During a new drug’s early preclinical development, the sponsor’s primary goal is to determine if the product is reasonably safe for initial use in humans, and if the compound exhibits pharmacological activity that justifies commercial development. When a product is identified as a viable candidate for further development, the sponsor then focuses on collecting the data and information necessary to establish that the product will not expose humans to unreasonable risks when used in limited, early-stage clinical studies.

Asphalion and EXTEDO provide you with a series of infographics on the regulatory requirements in different regions. This infographic is focused on INDs for US FDA.

Please complete the form to get the free download link.

[contact-form-7 id=”7406″ title=”Form IND”]

Search News & Events

  • Filter by category

Share

Related news and events

New! Clinical Data Publication (Policy 0070) re-launch

The scope of the policy relates to clinical data, composed of clinical reports and individual patient data (IPD), submitted under the centralised marketing authorisation procedure after the effective date (see chapter 4.3. for further information), either using the common technical document (CTD) format or another format

NEW! | The 3rd eAF-PMS Newsletter has been published on the EMA website!

This 3rd edition of the eAF-PMS
Newsletter highlights the latest news,
upcoming events and activities planned
for the next months. An updated
timeline of the web-based Human
Variations electronic application
form (eAF) accessible from the
Product Lifecycle Management
(PLM) Portal is now available to all
interested stakeholders. The timeline
highlights important milestones to be
achieved in the upcoming months with
regards to the release of new
functionalities, User Acceptance Testing
(UAT) and start of the transition period.
A version of the timeline highlighting
impacts on the eAF users in the
different periods is also available for
consultation.
If you are interested in the progress of

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting